negative result (say, at day 31 of a conceptual cycle) would also reliably induce menstruation. Moreover, RU 486 inhibits ovulation when administered at midcycle before the appearance of the luteinising hormone surge, indicating a further contraceptive possibility for the antiprogesterones (R L Collins *et al*, G Schaison *et al*, papers delivered at seventh international congress of endocrinology, Quebec City, 1984). Though these actions chart quite new territory in the regulation of fertility, several problems lie ahead. Regular administration of an antiprogesterone as a monthly contraceptive has potential difficulties; if it was given on day 31 of a conceptual cycle chorionic gonadotrophin secreted from the early (and aborting) embryo might remain in the maternal circulation for several days because of its long plasma half life. That might in turn sustain the corpus luteum and the secretion of progesterone for long enough to delay the return of normal ovarian folliculogenesis. The patient would be unlikely to ovulate 14 days after the start of her menses—and could, therefore, take the antiprogesterone steroid at an inappropriate, preovulatory time in her next cycle.

Antiprogesterone drugs may have a further use in the induction of labour in late pregnancy, because they appear to release prostaglandins from human endometrium.¹⁰ We do not know, however, whether antiprogesterones cross the placenta and whether they can affect the fetus directly. Placental progesterone seems an important substrate for the fetal synthesis of cortisol as the fetal adrenal lacks the 3 β hydroxysteroid dehydrogenase enzyme necessary for biosynthesis of cortisol from pregnenolone. An antiprogesterone might, therefore, reduce fetal secretion of cortisol and interfere with glucocorticoid dependent processes such as the production of surfactant in the fetal lung, quite apart from any concomitant antagonist action on glucocorticoid receptors.

These drugs might also offer a new medical treatment for Cushing's syndrome. In keeping with its binding to the glucocorticoid receptor RU 486 raises concentrations of adrenocorticotrophic hormone and cortisol in monkeys and in man.^{11 12} This antiglucocorticoid action occurs at a substantially higher dose than the antiprogesterone effect, suggesting a margin of safety in pregnant patients who might later require curettage to complete emptying of their uterus. The induction of anaesthesia in such women does not alter their cortisol secretory response to this stress and does not interfere clinically with their anaesthetic.^{8 9}

All these developments represent a real breakthrough in the regulation of fertility. Several pharmaceutical companies have given priority to the development of antiprogesterones, aiming at developing drugs which specifically antagonise through the progesterone receptor without binding to the glucocorticoid receptor.^{5 13} If their efficacy is proved the progesterone receptor antagonists will herald a new contra-gestational approach to fertility control and raise several critical medical, moral, and legal questions (E E Baulieu *et al*, paper delivered at CIBA Foundation symposium No 115, November 1984). Firstly, what are the risks to the fetus in early pregnancy if the patient takes an incomplete course of antiprogesterone treatment? Secondly, will prescription of such drugs be confined to hospitals or allowed on the NHS by general practitioners? Thirdly, how should the demands of women for their right to choose in this new aspect of gynaecology be addressed? Should antiprogesterones be available without prescription? And, finally, is it indeed legal to prescribe these medicines in Britain? In England and Wales abortion is taken to include

all procedures performed from the time of implantation.¹⁴ Giving an antiprogesterone drug to a woman whose period is delayed by two or three days may therefore be an offence under the 1967 Abortion Act. By contrast, Scots Common Law takes abortion to mean those procedures performed from the time that the woman can be shown to be "with child" by reasonably available methods, which is usually accepted as six to eight weeks of pregnancy. Similar laws requiring proof of pregnancy are widespread throughout the Commonwealth and would allow antiprogesterones to be used in those countries without legal liability for abortion.

DAVID L HEALY

Lecturer in Obstetrics and Gynaecology,
University of Edinburgh,
Edinburgh EH3 9EW
(Present address: Prince Henry Hospital,
Melbourne 3004,
Australia)

HAMISH M FRASER

Senior Scientist,
Medical Research Council Reproductive Biology Unit,
Centre for Reproductive Biology,
Edinburgh EH3 9EW

- 1 Mora G, Faundes A, Johansson EDB. Lack of clinical contraceptive efficacy of large doses of R2323 given before implantation or after a missed period. *Contraception* 1974;12:211-20.
- 2 Gu Z, Chang MC. A-nor steroids as post-coital contraceptives in the hamster with special reference to the transport and degeneration of eggs. *Contraception* 1979;20:549-57.
- 3 Hahn DW, McGuire JL, Chang MC. Contragestational agents. In: Zatuchni GI, Labbock MH, Sciarra JJ, eds. *Research frontiers in fertility regulation*. Hagerstown: Harper and Row, 1980:173.
- 4 Van der Spuy ZM, Jones DL, Wright CSW, *et al*. Inhibition of 3-beta-hydroxysteroid dehydrogenase activity in first trimester human pregnancy with trilostane and WIN 32729. *Clin Endocrinol* 1984;39:521-32.
- 5 Philibert D, Deraedt R, Tournemine C, Mary I, Teutsch G. RU 38486—an antiglucocorticoid with a new mechanism of antihormonal activity. *J Steroid Biochem* 1982;17:68.
- 6 Healy DL, Baulieu EE, Hodgen GD. Induction of menstruation by an antiprogesterone steroid (RU 486) in primates: site of action, dose-response relationships and hormonal effects. *Fertil Steril* 1983;40:253-7.
- 7 Herrmann W, Wyss R, Riondel A, *et al*. The effects of an antiprogesterone steroid on women; interruption of the menstrual cycle and of early pregnancy. *Comptes Rendus* 1982;294:933-8.
- 8 Kovacs L, Sas M, Resch BA, *et al*. Termination of very early pregnancy with RU 486—an antiprogesterone compound. *Contraception* 1984;29:399-410.
- 9 Swahn ML, Cekan S, Wang B, Lundström V, Bygdeman M. Pharmacokinetic and clinical studies on RU 486 for regulation of fertility. In: Segal S, Baulieu EE, eds. *Proceedings from a Rockefeller Foundation symposium in Bellagio, Italy*. (In press.)
- 10 Kelly RW, Healy DL, Cameron MJ, Cameron IT, Baird DT. RU 486 stimulates PGF_{2α} production in isolated endometrium cells in short term culture. In: Segal S, Baulieu EE, eds. *Proceedings from a Rockefeller Foundation symposium in Bellagio, Italy*. (In press.)
- 11 Healy DL, Chrousos GP, Schulte HM, *et al*. Pituitary and adrenal responses to antiprogesterone and anti-glucocorticoid steroid RU 486 in primates. *J Clin Endocrinol Metab* 1983;57:863-5.
- 12 Gaillard RC, Riondel A, Muller AI, Herrmann W, Baulieu EE. RU 486: a steroid with antiglucocorticoid activity that only disinhibits the human pituitary-adrenal system at a specific time of day. *Proc Natl Acad Sci USA* 1984;81:3879-82.
- 13 Neef G, Sauer G, Seeger A, Wiechert R. Synthetic variations of the progesterone antagonist RU 38486. *Tetrahedron Letters* 1984;25:3425-8.
- 14 Cook RJ, Dickens BM. *Emerging issues in Commonwealth abortion laws, 1982*. London: Commonwealth Secretariat Publications, 1983.

Who should have an intraocular lens?

Should we advise our patients to have a lens implant after removal of their cataracts?

Replacement of a cataractous lens by an equivalent implant of plastic has many advantages over the traditional pebble spectacles. These limit clear vision to a central field, are initially very distorting and clumsy, and prevent the use of the eyes in unison unless the fellow eye is also aphakic. Contact lenses may minimise these disadvantages, but they bring problems of their own—particularly for the elderly, who along with poor sight often have shaky or arthritic hands and so find them hard to manipulate. So the appeal of the implant is enormous, most patients have heard about them, and many are disappointed if their eye surgeon declines to provide this undoubted benefit.

It is now 35 years since that first lenticulus was inserted at St Thomas's Hospital, initiating a controversy that has swollen journals, provoked the ingenuity of technologists and the polemics of their advocates, and resulted in over 20 national intraocular lens societies and a flood of congresses (including a three day international intraocular lens congress at Harrogate in September 1984), in which the indications, techniques, and minuscule alterations in design were disputed as warmly as ever. The overall legitimacy of implants is fully accepted, but in most other aspects consensus still seems far away.

Well over 100 patterns of implant have already been marketed; and though the essential requirements are now fairly well accepted refinements continue unabated. These are issues of concern only to the specialist, however, and until there is established evidence of priority the individual surgeon may reasonably continue to use the type and procedure with which he feels most at ease. Apparently most implants in Britain are now almost equally divided between the pupil supported lenses after intracapsular extraction and the (increasingly popular) posterior chamber lenses within the lens capsule after extracapsular extraction; the various types of anterior chamber lenses take third place.¹

The real problem is the risk of complications. The most common and most damaging is injury to the corneal endothelium, leading to gross loss of vision from intractable corneal oedema, which corneal grafting cannot always rectify. These endothelial cells have negligible powers of regeneration, and their population diminishes throughout life; should it fall below a critical level aqueous can no longer be excluded from the cornea, which then becomes opalescent. So damage to the endothelium when the implant is being introduced may not only cause an immediate (and disastrous) oedema but even if insufficient to reduce the cell population below a critical level at once it may well bring nearer the day when the population does become too sparse, and oedema (bullous keratopathy) ensues. Thus the failure rate of implant surgery may well increase as the years pass, and for this reason most surgeons normally reserve the use of implants for the elderly with a short life expectancy. In a recent follow up at Oxford two eyes had corneal oedema three years after surgery, but five years later nine patients (12% of the 77 survivors) were affected,² and this has been paralleled by figures from other long term follow ups.^{3,4} As a grim reminder we find in Britain⁵ as in the United States (R Lindstrom, personal communication) that bullous keratopathy due to implants has now become the most common indication for corneal grafting.

The incidence of bullous keratopathy—as of other direct complications (including dislocation of the implant and persistent uveitis)—has steadily declined, however, as a result of improvement in techniques, instrumentations, and medication, along with the gradual elimination of the less satisfactory types of implant and better selection of patients. So this increasing risk of corneal damage as the postoperative years pass may soon become less formidable.

On the other hand, the gratifyingly low rate of complications in most published series does not reflect the frequency of disasters in the world at large, nor indeed do such reports always provide really adequate documentation and follow up. And the integrity of the results is further impeached when we discover that some eye doctors have a direct (but concealed) financial interest in promoting certain types of lens.⁶

Unhappily, the adoption of this major clinical advance of such wide and unquestioned benefit has been darkened by

alien commercial pressures and immoderate publicity—reflected in the contrasting popularity of implants among Western countries: from about 70% of cataract operations in the United States to 46% in Britain,¹ and probably nearer 20% elsewhere in western Europe.⁷ Furthermore, the absence of any real consensus on the indications for implant surgery leaves the field wide open, with a few enthusiasts inserting lenses into the eyes of children or already damaged eyes while at the other end of the spectrum many surgeons still decline to use them at all. It could be added that the market price of such lenses is rarely less than £100 (at nearly £10 000 a month at Moorfields their cost is greater even than the budget for contact lenses and a quarter of the total drug bill). This cost may conceivably be justified in terms of fewer outpatient visits afterwards and an improvement in the quality of vision, but this has already forced some British hospitals to curtail their use of lenses.¹

Thus the accepted indication for an implant is an otherwise sound eye with an advanced cataract, especially if the fellow eye is not only healthy but retains good vision, in an elderly patient (over 60) who is unlikely to cope with spectacles or contact lenses. Younger adults deserve implants if they have especial need for binocular vision (the other eye having good vision) and cannot tolerate contact lenses because of sensitivity and so on.

In still younger age groups implants are recommended only when the circumstances are very exceptional, when the surgeon himself is an expert, when follow up will be scrupulous (the lens may also need to be replaced, with doubled risks, in the case of a growing child), and when the patients are fully aware of the pros and cons.¹ Indeed, all patients should be informed of the added morbidity—about a 5-10% risk overall—and this applies with greater force when the eye is already damaged or when the fellow eye is imperfect. Simpler forms of implants are well within the compass of any experienced eye surgeon, as long as he knows the special risks and will provide scrupulous postoperative care, which often entails protracted use of topical steroids and of pilocarpine when the lens is held by the pupillary sphincter.

Implants are less often justified in patients with a long-standing myopia, especially when this is over about 5 dioptres, for the removal of an opaque lens may largely neutralise their myopia (and the implant also carries a slightly increased risk).

These reservations have already been sadly stretched by surgeons who are most vulnerable to commercial and social pressures and whose technical confidence shrouds the manifest need for longer term follow ups. One fine day implantation may become almost routine, especially if we can show that the new materials and methods have lived up to their promise. But not yet.

P D TREVOR-ROPER

Consultant Ophthalmic Surgeon,
London NW1 4LJ

- 1 Wong D, Steele ADMcG. Survey of intraocular lens implantation in the UK. *Trans Ophthalmol Soc UK* (in press).
- 2 Noble M, Cheng H, Jacobs P, Salmon J, McPherson K. Long-term follow-up of intraocular implants: the first 127 compared with the latest 100 in the same style in a span of 9 years. *Br J Ophthalmol* 1984;68:373-8.
- 3 Rich W. *Intraocular lenses and mobility of the aged*. Laboratoires Martinet, 1979. (Clinique Ophthalmologique No 4.)
- 4 Drews RC. The Medallion lens five years later. *American Intra-ocular Implant Society Journal* 1981;7:49-54.
- 5 Casey TA. Corneal grafting in the patient at high risk. *Trans Ophthalmol Soc UK* (in press).
- 6 Roper-Hall MJ. Sophistication in intraocular lens surgery (Raynor lecture). *Trans Ophthalmol Soc UK* (in press).
- 7 Dallas NL. Intraocular lenses at the crossroads. *Trans Ophthalmol Soc UK* 1981;101:450.